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ABSTRACT
Objective: In this concise and systematic review, the trend of using major medication modalities prescribed for refractory obsessive-compulsive 
disorder (OCD), including serotonin-specific reuptake inhibitors (SSRIs) and second-generation antipsychotics (SGAs) are discussed.
Methods: We systematically searched PubMed and Cochrane Central Register of Controlled Trials (CENTRAL) systematically using Mesh terms. OCD 
is extremely disabling and associated with considerable depression and other serious psychiatric illnesses.
Results: Through databases, we found 78 randomized clinical trials (RCTs), which included selective SSRI compared with routine drug therapy or 
placebo. Out of these 78 studies, 62 studies were conducted on adult patients with OCD, comprising 7920 cases. While only 16 RCTs were performed 
on children and adolescents with OCD, including 1313 people. We found 24 clinical trial studies related to SGAs, of which were conducted on adult 
patients with OCD, including 992 cases.
Conclusion: As our data showed among the SSRIs, fluvoxamine has been particularly well studied and used in RCTs in both children and adolescents with 
OCD. According to the summary of our review, it will be better when therapists use SGAs in the early treatment programs of refractory OCD. Thus, considering 
our reviewed, it seems that the first choice of early treatment programs of refractory OCD is fluvoxamine in combination with quetiapine or aripiprazole.
Keywords: Obsessive-compulsive disorder, Refractory, Second-generation antipsychotic drugs, Selective serotonin reuptake inhibitors.
INTRODUCTION
Obsessive-compulsive disorder (OCD) is a mental health condition with 
an unwanted, unpleasant thought, image, or urge that repeatedly enters 
a person’s mind. OCD affects about 2-3% of people over the course of 
their lifetimes [1,2]. OCD is the result of common psychological social and 
genetic factors interaction [3]. In the biological factors could mention the 
serotonin disorder in the brain, which for the treatment of this aspect, 
drug treatment is recommended to set serotonin in the brain.
Drug treatment is one of the most common methods of treatment 
of acute agitation in patients with clinical mental health disorders. 
Antipsychotic drugs are, therefore, used in the acute treatment, chronic 
psychotic disorders, and other psychiatric conditions [4,5]. First-
generation antipsychotic medications (FGAs), which are also known 
as classical neuroleptic or traditional antipsychotics, which typically 
used to treat psychosis such as schizophrenia, acute mania, agitation, 
and other psychiatric conditions [6]. The FGAs act through blocking the 
dopamine (DAT) D2neuro-receptor, which leads to the development of 
a subsequent series of new antipsychotics [7]. According to the potency 
of FGAs in binding to DAT D2neuro-receptor, these drugs divided into 
two categories include low and high potency groups [8,9]. Some of 
the reported complications compose dyskinesia, hyperkinesia, and 
involuntary movements in the face and extremities [10]. Second-
generation antipsychotic drugs (SGAs) that were introduced in 1989, 
which is also known as atypical antipsychotics are generally lower risk 
of extrapyramidal side effects compared with FGAs [10]. However, these 
drugs generally cause higher rates of weight gain and life-shortening 
metabolic disturbances, although side effects of any medication profile 
are different [11].
Selective serotonin reuptake inhibitors (SSRI), deal with neurochemical 
imbalance that is the key reason in mental health disorders [12,13]. 
People with acute mental health condition, suffer from a lack of 
serotonin in certain areas of the brain [14]. Serotonin is a chemical 
neurotransmitter that plays an important role in the mood regulation, 
is one of the key factors in lack of balance in mood disorders such as 
anxiety and depression [15]. SSRI has serotonin reuptake reduction in 
specific neurons, causing an increase in the brain serotonin and reduce 
the symptoms of mental health disorders. SSRI, in general, are safer 
than others but have their own side effects, which are usually sexual, 
metabolic, and gastrointestinal [16-18].
In patients with OCD, the response to medication should be 
evaluated after a time period of about 8-12-w. This time is usually 
more than the time period of the response to medication in patients 
with depression (3-4 w). Of course, the time may vary slightly, but 
mainly in the OCD treatment, the patient needs more time and 
dosage as well.
The main goal of medication is to reduce obsessive thoughts and actions 
so that the patient can naturally reduce activity and performance. 
Usually, 25-35% in the Yale-Brown Obsessive Compulsive Scale 
(Y-BOCS) considered as a favorable clinical response [19]. Currently, 
about 40% to 60% of patients show significant improvement by taking 
first SSRI drug, but few responses to drugs are very high [20,21].
The latest available systematic reviews on antipsychotic therapies in 
resistant OCD are done from 2005 to 2006 [22,23]; thus, many new 
relevant researches have been published, an update of the current 
available literature seems necessary. We aimed to systematically 
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evaluate the effects of SSRI compared with SGAs considering all 
published randomized clinical trials (RCT) studies for people with OCD.
Pharmacology
It seems that the FGAs and SGAs inhibit postsynaptic DAT D2 receptors 
in the brain. Several studies attest to the role of DAT D2 receptors in 
the antipsychotic drugs activity, including connections between these 
drugs and receptor and the clinical potency. Functional imaging studies 
show that 60-65% of DAT D2 receptors should be tackled by the effect 
of antipsychotic medications [24,25]. SGAs also bind to serotonin 
receptors that increase their affinity for connection to DAT D2 receptors, 
which this effect is not seen in the FGAs [26]. Largely for this reason, 
serotonin receptors may reduce the risk of extrapyramidal side effects 
of most second-generation drugs, known as atypical antipsychotics, 
compared to the first-generation agents, especially in case of high 
potency drugs [27]. SSRIs primarily inhibit serotonin transporter 
(SERT) and the uptake of serotonin (5-HT) in the brain. These drugs 
also have controversial effects on DAT and norepinephrine transporters 
(NET). SSRI play a role in improving depression symptoms through 
inhibiting the binding of the neurotransmitter, serotonin (5-HT), to 




We included all double-blind, randomized controlled trials.
Types of participants
We included studies in which people with a primary diagnosis of OCD 
according to Diagnostic and Statistical Manual-III (DSM-III)/DSM-
IV or International Classification of Diseases-10 both children and 
adults. We did not exclude any OCD trials in participants with a serious 
concomitant medical illness.
Types of interventions
SGAs and SSRIs could be given as a monotherapy or as adjunctive 
therapy compared with placebo or other antidepressants. There were 
no limits in terms of study duration.
Search methods for identification of studies
We searched PubMed and Cochrane Central Register of Controlled 
Trials (CENTRAL) systematically up to 29/01/2016. The search 
terms used were: ((Obsess* or compul* or OCD) and “atypical 
antipsychotic*” or “second-generation antipsychotic*” or “second-
generation antipsychotic*”) and ((obsess* or compul* or OCD) and 
“atypical antipsychotic*” or “second-generation antipsychotic*” or 
“second-generation antipsychotic*” or “SSRI”)). We also searched www.
clinicaltrials.gov using search terms for intervention and condition, 
e.g., SGAs AND OCD, SSRI and OCD. No language restrictions were 
applied.
RESULTS
SSRI in refractory OCD
Through databases, we found 78 RCTs, which included SSRI compared 
with routine drug therapy or placebo (Table 1). Out of these 78 studies, 
62 studies were conducted on adult patients with OCD, comprising 
7920 cases. While only 16 RCTs were performed on children and 
adolescents with OCD, including 1313 people.
Comparing these two groups of patients revealed that fluvoxamine was 
most frequent drugs used in adults; hence, most frequent drugs used in 
children were sertraline (Fig. 1).
Of 78 studies, fluvoxamine was the most frequent drugs used in 
patients with refractory OCD with 26 (33.33%) frequency followed by 
paroxetine, sertraline, and fluoxetine (Fig. 2).
Four SSRIs have been approved for the adult OCD treatment by 
the FDA so far, including fluvoxamine, fluoxetine, sertraline, and 
paroxetine. Among these five SSRIs, only four drugs have also been 
approved for treatment of pediatric OCD, including clomipramine, 
fluoxetine, fluvoxamine, and sertraline [102]. Fluvoxamine is one of 
the SSRI drugs, which is primarily used to treat OCD, social anxiety 
disorder, major depression, management of obesity, and bulimia, 
schizophrenia, and panic disorder. Many researchers believe that the 
imbalance in neurotransmitters causes depression and other mental 
disorders. Fluvoxamine inhibits serotonin reuptake that causes mania 
and euphoria. Furthermore, fluvoxamine has also been approved 
by the Food and Drug Administration (FDA) for the OCD treatment. 
Antidepressants such as fluvoxamine may increase the risk of suicide in 
children and young adults even in the first few weeks of consumption. 
This drug was the first SSRI licensed for use in adults, as well as for 
children, in OCD in the United States and Japan [103]. A number of RCT 
studies have confirmed the efficacy of fluvoxamine in improving the 
symptoms of OCD, and subsequently reducing the disruption it causes 
in daily life as well [28,33,39,42,44,46]. Trend of using SSRI in RCTs on 
refractory OCD also showed a decreasing pattern for fluvoxamine and 
paroxetine (Fig. 3).
No SSRI has been verified to be more effective than others in patients 
with OCD. Nevertheless, patients may individually respond more 
satisfactorily to one SSRI than to another. The most effective SSRI in 
any given patient is difficult to predict. Therefore, considering cost, 
available formulations, side effect profile, and half-life may help the 
selection. Among different SSRIs, currently only generic forms of 
clomipramine, citalopram, fluoxetine, fluvoxamine, and paroxetine are 
available.
SGAs in refractory OCD
We searched PubMed and Cochrane Central Register of Controlled 
Trials (CENTRAL), which lead us to 24 clinical trial studies (Table 2). 
These 24 trials were conducted on adult patients with OCD, including 
992 cases.
Of 24 studies, risperidone and quetiapine were the most frequent SGA 
drugs used in patients with refractory OCD with 8 (33.33%) frequencies 
in both (Fig. 4).
The trend of using SGAs in RCTs on refractory OCD also showed 
an increasing pattern only for aripiprazole, whereas in the case of 
olanzapine and quetiapine was decreasing (Fig. 5).
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Mixed SSRI and SGAs in refractory OCD
Through our search, we included only 4 RCTs with 252 participants 
on SGAs plus SSRIs in refractory OCD patients (Table 3). All trials 
investigated the effects of adding SGAs to SSRIs with the duration of 
more than 6-w.
DISCUSSION
Drug treatment is one of the most common methods of treatment of 
patients with clinical mental health disorders such as OCD. Although 
using SSRI drug in trials is beneficial with a selective efficacy in OCD, up 
to 40% to 60% of OCD patients claim no satisfactory outcome [20,21]. 
As yet little is known about the efficacy and side effects of SGAs and 
SSRI in people suffering from OCD.
Due to the irrational and excessive nature of OCD, the treatment of 
refractory OCD is the major concern of psychiatrists. Unfortunately, 
despite advance in therapy and developing new and effective treatment 
modalities in the treatment of OCD, majority of patients suffering from 
OCD and at an increased risk of developing the disorder. One of the 
reasons can be the diverse nature of OCD. Considering DSM-III, DSM-
III-R, and DSM-IV, OCD was classified as an anxiety disorder, whereas in 
ICD-10, this disorder was separated from the anxiety disorders. Recent 
advances in understanding illness anxiety have led to the question of 
whether OCD should no longer be classified as anxiety disorders in 
DSM-V or not [131,132].
According to the trials reviewed in this article can say that both 
fluvoxamine and quetiapine are the drug of choice and first-line agents 
in the early treatment of OCD. However, due to the growing trend of 
aripiprazole seems that soon this antipsychotic agent replaced the use 
of quetiapine in the treatment of refractory OCD. As the treatment of 
refractory OCD generally requires high doses of SSRIs, this higher 
dose increases the side effects, especially loss of sexual drive [133]. 
In agreement with our findings, Irons in a review studied the use of 
fluvoxamine in the treatment of mental health disorders, claimed 
that this SSRI agent is well-tolerated and does not cause sedation or 
Fig. 2: Percentage of used various serotonin-specific reuptake 
inhibitors in clinical trials on patients with refractory obsessive-
compulsive disorder. FLU: Fluvoxamine, ESC: Escitalopram, 
MT: Medication therapy, including citalopram (CIT), ESC, FLU, 
paroxetine (PAR), Clomipramine (CLO), Venlafaxine (VEN); 
Risperidone (RIS); Fluoxetine (FLX); Sertraline (SER)
Fig. 3: Trends of the most frequent used serotonin-specific 
reuptake inhibitors in obsessive-compulsive disorder from 
1996 to 2016
Fig. 4: Percentage of used various SGA in clinical trials on patients 
with refractory obsessive-compulsive disorder. PLP: Paliperidone, 
APZ: Aripiprazole, QPE: Quetiapine, OLP: Olanzapine, 
RIL: Riluzole, RIS: Risperidone
Fig. 5: Trends of the most frequent used serotonin-specific 
reuptake inhibitors in obsessive-compulsive disorder from 1996 
to 2016
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Table 1: Summary of recent clinical trials that was found by initial search










FLU BT 12 week 48 patients with OCD 
resistant to a BT
Landsheer 
et al. 2015, 
Netherlands [28]













SER CBT 16 week 54 children and 
adolescents (age 
7-17 years) with primary 
OCD
Skarphedinsson 
et al. 2015, 
Norway [30]
Randomized, parallel 




MT MT+CBT 12 week 124 youth (aged 7 to 
17 years) with a primary 
OCD
Conelea et al. 
2014, USA [31]
Double-blind clinical trial DUOCS FLX FLX+CBT 13 week 30 cases with OCD Giasuddin 












YBOCS PAR PBO 12 week 36 adults with OCD Humble 
et al. 2013, 
Sweden [34]
Randomized open trial YBOCS FLX CBT 12 week 160 cases with OCD Jakubovski 




TEASAP score SER PBO 4 week 56 youth (aged 7-17) 
with OCD
Bussing et al. 
2013, USA [36]
Randomized clinical trial YBOCS FLX CBT 12 week 29 adult patients with 
OCD





YBOCS FLX PBO 8 week 31 adult patients with 
OCD




YBOCS FLU CBT 12 week 118 subjects with OCD van Balkom 





YBOCS FLX CBT 12 week 38 adult patients with 
OCD







SER CBT 12 week 46 patients with a 
primary OCD












YBOCS-SC SER PBO 12 week 112 youth (aged 7-17) 
with OCD




Y-BOCS score, side 
effects




YBOCS FLX PBO 8 week 42 adult patients with 
OCD








CY-BOCS, CGI FLX CIT 6 week 29 children and 
adolescents (7-18 years) 
with OCD 
Alaghband-Rad 








ESC PBO 12 week 466 adults with OCD Stein et al. 2008, 
South Africa [48]
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YBOCS PAR VEN 12 week 91 outpatients with OCD Denys 
et al. 2007, 
Netherlands [50]
A double blind placebo 
control trial.
















Y-BOCS ESP PBO 24 week 320 patients with OCD Fineberg et al. 
2007, UK [53]
A randomized clinical 
trial
Y-BOCS, CGI SER CBT 12 week 46 outpatients with an 
OCD




Y-BOCS, CGI SER PBO 16 week 66 adult subjects with 
OCD





Y-BOCS, CGI PAR VEN 12 week 42 outpatients with OCD Denys 
et al. 2006, 
Netherlands [56]
A randomized, controlled 
trials
Y-BOCS, CGI FLU CBT 12 week 122 outpatients with 
primary OCD
van Oppen 





Y-BOCS, CGI FLU PBO 12 week 117 outpatients with 
OCD
Hollander et al. 
2005, USA [58]
A randomized, controlled 
trial
Y-BOCS SER CBT 12 week 40 subjects (9 and 
17 years) with OCD





Y-BOCS PAR VEN 24 week 96 patients with OCD Tenneij 
et al. 2005, 
Netherlands [60]
A randomized, placebo 
controlled trial










Y-BOCS score FLU BT 12 week 10 patients with primary 
OCD




Y-BOCS score PAR VEN 12 week 150 patients with 
primary OCD
Denys 







SER PBO 12 week 37 adult patients with 
OCD





CY-BOCS SER CBT 12 week 112 patients (7-17 years) 





CY-BOCS PAR PBO 10 week 207 Children (7-11 years 
of age) and 
adolescents (12-17 years 
of age)




Y-BOCS, CGI, HDS CIT PBO 12 week 49 adult patients with 
OCD





Y-BOCS PAR PBO 12 week 191 patients with a 
primary OCD




Y-BOCS, HAM EPA EPA+PBO 12 week 49 adult patients with 
OCD
Fux et al. 2004, 
Israel [67]




study of fixed doses
Y-BOCS PAR PBO 12 week 348 outpatients with 
OCD
Hollander et al. 
2003, USA [69]
Flexibly dosed open-label Y-BOCS PAR PBO 24 week 2263 outpatients with 
OCD
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impact on relapse 
prevention
PAR PBO 24 week 3105 outpatients with 
OCD





Y-BOCS, HAM PAR VEN 12 week 150 patients with 
primary OCD
Denys 






PAR VEN 12 week 140 patients with 
primary OCD
Denys 




















CY-BOCS, CGI PAR VEN 12 week 73°CD patients Albert et al. 
2002, Italy [77]







FLU PBO 52 week 130 patients with 
primary OCD**





YBOCS, CGI SER FLU 24 week 150 patients were OCD Bergeron 
et al. 2002, 
Canada [79]
A large randomized 
placebo-controlled trial
YBOCS, CGI CIT PBO 12 week 71 patients were OCD Stein et al. 2001, 
South Africa [80]






SER PBO 12 week 132 Children (6-12 years; 
n=72) and 
adolescents (13-18 years; 
n=65) with OCD





CY-BOCS FLU PBO 13 week 103 Children (7-17 years) 
with OCD




YBOCS, BABS PAR PBO 12 week 36 patients were OCD Humble 






CY-BOCS FLU PBO 10 week 120 Children (7-17 years) 
with OCD










PAR PBO 6 week 14 treatment-resistant 
OCD patients







FLU BT 12 week 10 children/adolescents 
with OCD








SER DPM 12 week 166 patients with OCD Hoehn-Saric 




Y-BOCS CIT CIT+CLO 12 week Sixteen adult outpatients 
with OCD
Pallanti et al. 
1999, Italy [90]
Open-label trial CY-BOCS, HAM, 
CGI
PAR PBO 12 week 20°CD outpatients (8 to 
17 years)
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and the Padua 
Inventory-Revised
FLU CT 16 week 117 patients with 
primary OCD
van Balkom 











SER PBO 12 week 107 children (6 to 
12 years) and 80 
adolescents (13 to 
17 years) with OCD





YBOCS FLU PBO 8 week 60°C patients Hohagen 





YBOCS FLX PBO 10 week 35 patients with primary 
OCD






scale, the CGIIS 
Scale, and the HRS 
for depression
FLU CIT 10 week 30 patients with primary 
OCD




Y-BOCS and CGIIS 
scales
FLU CLO 8 week 26 individuals with OCD Milanfranchi 




Y-BOCS and CGIIS 
scales
FLU CLO 8 week 55 individuals with OCD López-Ibor 
et al. 1996, 
Spain [101]
*The diagnosis of OCD based on DSM‑IV‑TR and a Y‑BOCS score of≥21, **The diagnosis of OCD based on DSM‑IV‑TR and a Y‑BOCS score of≤19. Y‑BOCS: Yale‑brown 
obsessive compulsive scale, MEM: Memantine, FLX: Fluoxetine, CIT, Including citalopram, ESC: Escitalopram, FLU: Fluvoxamine, PAR: Paroxetine, CLO: Clomipramine, 
VEN: Venlafaxine, ESC: Escitalopram, SER: Sertraline, BUP: Bupropion, GSA: Gambling severity assessmen, CGIIS: Clinical global impression improvement and severity, 
GA: Global assessment, ADHDR: Attention-deficit/hyperactivity disorder rating, SD: Sheehan disability, rTMS: Transcranial magnetic stimulation, RIS: Risperidone, 
VEN: Venlafaxine, HDS: Hamilton depression scale, DS: Depressive symptoms, CGI: Clinical global improvement, PIN: Pindolol, CT: Cognitive therapy, CIT: Citalopram, 
HRS: Hamilton rating scale, CLO: Clomipramine, BT: Behavior therapy
Table 1: (Continued)
Design Outcome Study arms Follow-up Participant* Author, year, 
countryDrug Placebo
A pilot randomized, 
placebo-controlled trial






quality of life, HDS, BABS
RIS PBO 8 week 100 patients with at least 
moderate OCD severity
Foa et al. 2015, 
USA [105]
Randomized clinical trial YBOCS RIS PBO 12 week 36 adults (aged 
18-70 years) with OCD





YBOCS, CGIIS PLP PBO 8 week 34 patients (aged 
24-67 years) with OCD










YBOCS APZ PBO 16 week 201 patients (20-70 years) 
with OCD





YBOCS APZ RIS 12 week 90 patients (18-65 years) 
with OCD









YBOCS QPE PBO 12 week 40 patients with primary 
OCD
Kordon et al. 2008, 
Germany [112]
Table 2: Summary of recent clinical trials that was found by initial
(Contd...)
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Y-BOCS QPE PBO 8 Week 40 therapy-resistant OCD 
patients
de Geus 
et al. 2007, 
Netherlands [113]
A double-blind, parallel 
group design









Y-BOCS RIS PBO 12 week 16 outpatients with OCD Li et al. 2005, 
USA [116]












Y-BOCS, CGI QPE PBO 8 week 40 patients with a primary 
OCD




Y-BOCS OLP PBO 6 week 26 patients (18 and 
65 years) with OCD





Y-BOCS, CGI RIS PBO 12 week 16 adult 
treatment-resistant OCD 
patients
Hollander et al. 
2003, USA [69]
Open-label, add-on trial Y-BOCS, CGI OLP PBO 12 week 21 adult OCD patients D’Amico et al. 
2003, Italy [121]




YBOCS, CGI QPE PBO 8 week 27 patients were 
refractory OCD
Atmaca 
et al. 2002, 
Turkey [123]
Open-label trial Y-BOCS RIS PBO 10 week 20 refractory OCD 
outpatients





Y-BOCS RIS PBO 12 week 36 refractory OCD 
outpatients
McDougle et al. 
2000, USA [125]
Open-label trial CY-BOCS CGI OLP PBO 8 week 10 patients with OCD Weiss et al. 1999, 
USA [126]
*The diagnosis of OCD based on DSM‑IV‑TR and a Y‑BOCS score of≥21, All patients were treated with 1 of the 2 following selective serotonin reuptake inhibitors: 
Fluvoxamine or sertraline. Y-BOCS: Yale-brown obsessive compulsive scale, RIL: Riluzole, PBO: Placebo, RIS: Risperidone, BABS: Brown assessment of beliefs, 
CGI: Clinical global improvement, PLP: Paliperidone, CGIIS: Clinical global impression improvement and severity, SMTC: Stress management training condition, 
APZ: Aripiprazole, QPE: Quetiapine, HDS: Hamilton depression scale, OLP: Olanzapine
Table 2: (Continued)
Table 3: Summary of recent clinical trials that was found by initial search




YBOCS CIT+QPE PBO 10 week 46 adult patients 
with OCD






PBO+FLX 12 week 54 patients with a 
primary OCD
Diniz et al. 2011, 
Brazil [128]
Randomized, controlled trial YBOCS EX/RP SMT 12 week 108 patients with 
OCD
Simpson et al. 
2008, USA [129]
A double-blind, placebo-controlled YBOCS OLP+FLU PBO+FLU 6 week 44 adults with OCD Shapira et al. 2004, 
USA [130]
*The diagnosis of OCD based on DSM‑IV‑TR and a Y‑BOCS score of≥21. Y‑BOCS: Yale‑brown obsessive compulsive scale, FLU: Fluvoxamine, CIT: Citalopram, 
QPE: Quetiapine, FLX: Fluoxetine, SMT: Stress management training, PBO: Placebo, EX/RP: Exposure/ritual prevention therapy
cognitive impairment. He also reported that this drug is associated with 
a low risk of sexual dysfunction, suicidality, and withdrawal reactions; 
thus, it is a safe SSRI agent even in overdose and has no considerable 
impact on cardiovascular system and body weight [103]. In a systematic 
review, Bloch et al. evaluated the efficacy of antipsychotic agents in 
treatment-refractory OCD on nine studies involving 278 participants. 
They claimed that there is sufficient evidence in the literature about 
the efficacy of haloperidol and risperidone, whereas evidence of the 
efficacy of quetiapine and olanzapine is unconvincing [22]. Contrary 
to their clime, we showed there sufficient evidence in the literature on 
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risperidone, as well as quetiapine and olanzapine. The difference is may 
be due to the difference in the date limitation in the search strategy. 
Recently, Veale et al. in a systematic review and meta-analysis on 14 RCTs 
including risperidone, quetiapine, olanzapine, and aripiprazole [134]. 
They concluded that a low dose of risperidone and aripiprazole can use 
cautiously as an antipsychotic agent in nonresponders to SSRIs. In other 
reviews, Arumugham and Reddy reported that antipsychotic agents, 
especially risperidone and aripiprazole have shown the best evidence 
in refractory patients with OCD [135].
CONCLUSION AND PERSPECTIVES
As our trends show, fluvoxamine was the most frequent SSRI used in 
patients with refractory OCD followed by paroxetine, sertraline, and 
fluoxetine. Hence, risperidone and quetiapine were the most frequent 
SGA drugs used in patients with refractory OCD. According to the 
summary of our review, it seems that the first choice of early treatment 
programs of refractory OCD will be fluvoxamine in combination with 
quetiapine or aripiprazole. Recently, the treatment of patients with OCD 
has improved dramatically. OCD is extremely disabling and associated 
with considerable depression and other serious psychiatric illnesses. 
Therefore, this disease represents an important area of medical need. 
The well-known disadvantages of the traditional antipsychotics have 
resulted in becoming the SSRIs first-line treatment for many mental 
health disorders such as OCD. As our data showed among the SSRIs, 
fluvoxamine has been particularly well studied and used in RCTs in both 
children and adolescents with OCD. According to the summary of our 
review, it will be better when therapists use SGAs in the early treatment 
programs of refractory OCD. Thus, considering our reviewed, it seems 
that the first choice of early treatment programs of refractory OCD is 
fluvoxamine in combination with quetiapine or aripiprazole.
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